Democratic Republic of the Congo & Gilead Sciences
2 shared events · Importance 3 · Last updated Jul 05, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Tech
Democratic Republic of the Congo: The Democratic Republic of the Congo is the epicenter of the Ebola outbreak and the location where the clinical trial is being conducted. The country is severely affected by the virus, with a high number of cases and deaths.
Gilead Sciences: Gilead Sciences is the developer of remdesivir, one of the antiviral drugs being evaluated in the clinical trial for Ebola. The company has donated doses of the drug for the study.
Apr 20, 2026 · 67 articles
Tech
Democratic Republic of the Congo: The Democratic Republic of the Congo (DRC) is experiencing the largest recorded outbreak of Ebola caused by the Bundibugyo ebolavirus, with 1,406 confirmed cases and 438 deaths. The new diagnostic test is vital for the DRC's efforts to control the outbreak.
Gilead Sciences: Gilead Sciences' antiviral drug remdesivir is being evaluated in combination with Mapp Biopharmaceutical's MBP134 antibody in a treatment trial for the Bundibugyo Ebola outbreak.
Jul 02, 2026 · 8 articles
NEWSDESK
Explore this relationship live
Track how Democratic Republic of the Congo and Gilead Sciences interact across events, view sentiment trends, and discover connected entities.
Open Dashboard